Showing results (91-100 of 177) with videos related to
Sort By:
Pageof 18
Bone Marrow Transplantation|September 8, 2020
Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host diseaseNatasha Kekre, Haesook T Kim, Julia Hofer, et al.Blood Advances|December 5, 2023
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AMLJoshua A Fein, Roni Shouval, Elizabeth Krieger, et al.Transplantation and Cellular Therapy|March 21, 2026
Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CIAnsh Mehta, Haesook T Kim, Arcita Pramudita, et al.Blood Advances|January 26, 2021
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamideBenedetta Rambaldi, Haesook T Kim, Carol Reynolds, et al.Blood Advances|September 4, 2020
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemiaHaesook T Kim, Conner J Shaughnessy, Sharmila C Rai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantationRafael Bejar, Kristen E Stevenson, Bennett Caughey, et al.Blood|December 17, 2015
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHDAna C Alho, Haesook T Kim, Marie J Chammas, et al.Blood Advances|September 28, 2021
Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitutionKatie Maurer, Haesook T Kim, Thomas M Kuczmarski, et al.Transplantation and Cellular Therapy|September 23, 2025
Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell TransplantationJessica S Little, Kyle M Hebert, Donna S Neuberg, et al.Transplantation and Cellular Therapy|July 15, 2022
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 TrialQaiser Bashir, Taiga Nishihori, Marcelo C Pasquini, et al.Pageof 18